MedTech Terms
    The authoritative reference
    All terms

    RWE for Reimbursement

    Real-world evidence used to support coverage and payment decisions.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    Real-world evidence - from registries, claims data, and EHRs - increasingly supports CMS coverage decisions, NICE technology appraisals, and EU JCA dossiers, particularly for technologies where RCTs are infeasible or have completed.
    What the regulation says
    Real-world evidence (RWE) is utilized by regulatory bodies and health technology assessment (HTA) agencies, such as the Centers for Medicare & Medicaid Services (CMS) in the US and the National Institute for Health and Care Excellence (NICE) in the UK, to inform coverage and reimbursement decisions, especially when randomized controlled trials (RCTs) are impractical or have been completed. The EU Joint Clinical Assessment (JCA) also considers RWE dossiers. The FDA provides guidance on the use of RWE, for example, in "Real-World Evidence Program, Guidance for Industry" (2023).

    What this means in practice

    Registry-based evidence (TVT, NCDR, ACC/STS) underpins coverage for structural heart and EP devices. Manufacturers must invest in registry strategy alongside trial strategy.

    Examples

    • A medical device manufacturer uses data from a post-market registry to demonstrate the long-term effectiveness and safety of a novel cardiac implant, leading CMS to expand its coverage policy.
    • A company submits an RWE dossier, including claims data and EHR extracts, to NICE to support a positive technology appraisal for a connected health solution for diabetes management.
    • After an initial randomized controlled trial, a MedTech firm collects RWE on a surgical robot through a dedicated real-world study, which is then used to negotiate favorable reimbursement rates with private payers.
    Common pitfalls
    • •Assuming RWE always replaces the need for premarket clinical trials, rather than complementing them, is a common error.
    • •Failing to establish robust data quality and governance for RWE collection can lead to rejections from reimbursement bodies.
    • •Ignoring the specific evidence requirements of different reimbursement authorities for RWE submissions can result in delays or denials.
    • •Underestimating the resources and expertise required to collect, analyze, and present RWE effectively is a frequent pitfall.

    Frequently asked questions

    Real-world evidence for reimbursement typically includes data from patient registries, electronic health records (EHRs), claims databases, and observational studies. These data sources provide insights into how devices perform in routine clinical practice.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Learning paths (1)

    Primary references

    2 sources
    Link health: 2 verified· last checked 2026-06-20
    AMA·1AdvaMed·1
    1. 1
      AMA CPT Resources
      Verified
      AMAama-assn.org
    2. 2
      AdvaMed - Payment & Coverage
      Verified
      AdvaMedadvamed.org

    Inline markers like [1] jump to the matching reference above.